Literature DB >> 9685520

Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo.

M Ito1, M Chokki, Y Ogino, Y Satomi, Y Azuma, T Ohta, M Kiyoki.   

Abstract

We compared the cytotoxic effects of alendronate (ALN) and incadronate (YM175) on isolated rabbit osteoclasts in vitro and on rats in vivo. In the in vitro experiment, each bisphosphonate was added to the culture of isolated osteoclasts at the final concentration of 3 x 10(-5), 3 x 10(-4), or 3 x 10(-3) M, and the amount of creatine phosphokinase (CPK) released into the medium was taken as an index of cytotoxicity at 5, 10, and 24 hours after the treatment. Also viability of osteoclasts, measured in terms of trypan blue exclusion, was assessed at 24 hours after the treatment. In YM175-treated groups, CPK activity in the medium increased in a concentration-dependent manner with time, and phase-contrast microscopic observation revealed damaged cell membranes and nuclear deterioration in YM175-treated osteoclasts. As a result, the viability of the osteoclasts was decreased at the concentrations of 3 x 10(-4) and 3 x 10(-3) M. However, in the ALN-treated groups, neither CPK activity nor viability of isolated osteoclasts changed significantly compared with control levels even at 3 x 10(-3) M for up to 24 hours. In the in vivo experiment, each bisphosphonate was administered separately to normal rats (7 weeks old, Sprague-Dawley) by intravenous injection at 1, 5, or 25 nmol/kg. Two days after the injection, the animals were euthanized, and the plasma Ca concentration and total CPK activity were measured. In YM175-injected rats, the CPK activity increased at 25 mmol/kg, and a slight decrease in the plasma Ca level was seen at this dose. In contrast, in ALN-injected rats, CPK activity did not increase even at 5 or 25 mmol/kg, and the plasma Ca level did decrease significantly compared with controls. Isozyme analysis revealed that, not only was CPK activity increased in the BB type in YM175-injected rats, it was also increased in the MB and MM types. In conclusion, alendronate, unlike YM175, does not have any cytotoxic effects on osteoclasts either in vitro or in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685520     DOI: 10.1007/s002239900505

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  5 in total

1.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

2.  The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration.

Authors:  Yumiko Ohbayashi; Fumi Nakai; Akinori Iwasaki; Takaaki Ogawa; Yuka Yamamoto; Yoshihiro Nishiyama; Minoru Miyake
Journal:  Odontology       Date:  2016-10-21       Impact factor: 2.634

3.  Medicinal surface modification of silicon nanowires: impact on calcification and stromal cell proliferation.

Authors:  Ke Jiang; Dongmei Fan; Yamina Belabassi; Giridhar Akkaraju; Jean-Luc Montchamp; Jeffery L Coffer
Journal:  ACS Appl Mater Interfaces       Date:  2009-02       Impact factor: 9.229

4.  Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model.

Authors:  Hiroya Senzaki; Takahiro Yasui; Atsushi Okada; Yasunori Ito; Keiichi Tozawa; Kenjiro Kohri
Journal:  Urol Res       Date:  2004-04-03

5.  Induction of creatine kinase release from cultured osteoclasts via the pharmacological action of aminobisphosphonates.

Authors:  Makoto Tanaka; Hiroshi Mori; Ryoji Kayasuga; Kazuhito Kawabata
Journal:  Springerplus       Date:  2015-02-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.